[Cardiovascular effects of human atrial natriuretic peptide during pediatric renal transplantation].
BACKGROUND
We evaluated the cardiovascular effects of human atrial natriuretic peptide (hANP) in the pediatric recipients undergoing renal transplantation.


METHODS
Anesthesia was maintained by inhalation of nitrous-oxide and isoflurane in oxygen. Intravenous infusion of hANP at a rate of 0.05 microg x kg(-1) x min(-1) was started on the anastomosis of the renal artery after the fresh frozen plasma had been loaded to achieve PCWP above 17 mmHg. We examined cardiovascular changes by using a pulmonary artery catheter and transesophageal echocardiography. The measurements were done before and after 15 minutes of hANP infusion.


RESULTS
An increase in CI and a reduction in PCWP were significant.


CONCLUSIONS
The low-dose infusion of hANP was useful in pediatric recipients undergoing renal transplantation for the optimal anesthetic care in view of the improvement of cardiovascular functions.
Terada
Takashi
T
First Department of Anesthesiology, Toho University School of Medicine, Tokyo 143-8541.
Hirano
Yohachiro
Y
Akutsu
Reika
R
Toyoda
Daisuke
D
Maki
Yuichi
Y
Ochiai
Ryoichi
R
D000293:Adolescent; D000769:Anesthesia, Inhalation; D009320:Atrial Natriuretic Factor / Q000008:administration & dosage*; D002302:Cardiac Output; D002407:Catheterization, Swan-Ganz; D002648:Child; D002675:Child, Preschool; D017548:Echocardiography, Transesophageal; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007430:Intraoperative Care; D016030:Kidney Transplantation; D008297:Male; D011669:Pulmonary Wedge Pressure
D009320:Atrial Natriuretic Factor